DNase I hypersensitive site (DHS)

A DNase I hypersensitive site (DHS) is a specific region of open, accessible chromatin that is highly vulnerable to cleavage by the DNase I enzyme. DHSs act as key markers for active regulatory DNA, such as promoters, silencers, and enhancers, indicating where transcription factors and regulatory proteins bind to control gene expression.

The Function of DHSs in the BCL11A Enhancer

The BCL11A gene plays a major role in human biology as the primary silencer of fetal hemoglobin. Naturally occurring genetic variations within the BCL11A enhancer are heavily associated with altering fetal hemoglobin levels, which is vital for managing β-globin disorders like sickle cell disease. Here is how DHSs function in the BCL11A enhancer:

  • Location and Discovery: The critical erythroid-specific BCL11A enhancer is located within intron-2 of the gene. Genome mapping reveals three distinct DHSs in this region, located roughly +55, +58, and +62 kilobases downstream of the BCL11A transcription start site (often termed DHS +55, +58, and +62). 

  • Transcription Factor Binding: Because these DHSs indicate open chromatin, they allow specific hematopoietic and erythroid transcription factors (such as GATA1, TAL1, and ATF4) to bind to the enhancer sequence. This binding loop drives the high expression of BCL11A in red blood cell precursors.
     
  • Impact of Genetic Variants: Many Single Nucleotide Polymorphisms (SNPs) associated with high fetal hemoglobin levels fall directly within these DHS peaks. For example, a common trait-associated SNP in the +62 DHS peak alters a binding site for GATA1/TAL1 transcription factors, reducing their ability to bind. This disrupts the opening of the chromatin structure, downregulates BCL11Aexpression specifically in erythroid cells, and subsequently allows fetal hemoglobin production to persist.

  • Therapeutic Application: The +55, +58, and +62 DHSs are active targets in genetic therapies for sickle cell disease and β-thalassemia. Modern gene-editing techniques (such as CRISPR-Cas9 or multiplex base editing) are used to precisely disrupt or mutate these DHS regions to mimic natural variants, thereby switching off BCL11A and reactivating fetal hemoglobin.